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Abstract
Background: The neurofilament is a major structural component of myelinated axons. Increased
cerebrospinal fluid (CSF) concentrations of the light chain of the neurofilament protein (NFL) can
serve as a sensitive indicator of central nervous system (CNS) injury. To assess whether
interrupting antiretroviral treatment of HIV infection might have a deleterious effect on the CNS,
we measured NFL levels in HIV-infected subjects interrupting therapy.
We identified subjects who had CSF HIV RNA concentrations below 50 copies/mL at the time
combination antiretroviral therapy was interrupted, and for whom CSF samples were available
before and after the interruption.
Results: A total of 8 subjects were studied. The median (range) CSF NFL level at baseline was
<125 (<125–220) ng/L (normal <250 ng/L). All 8 subjects exhibited an increase in CSF and plasma
HIV RNA after stopping therapy, accompanied by intrathecal immunoactivation as evidenced by
CSF lymphocytic pleocytosis (7/8 patients) and increased CSF neopterin concentration (5/6
patients). Three subjects showed a consistent increase in CSF NFL, rising from <125 ng/L to a
maximum of 880 (at day 148), 1,010 (day 58) and 10,930 ng/L (day 101). None exhibited new
neurological symptoms or signs, or experienced functional deterioration during the period off
treatment; of 5 who underwent brief quantitative neurological testing, none showed worsening
performance.
Conclusion:  These findings suggest that resurgence of active HIV replication may result in
measurable, albeit subclinical, CNS injury. Further studies are needed to define the frequency and
pathobiological importance of the increase in CSF NFL.
Background
The mortality and morbidity of HIV infection have sub-
stantially decreased in the developed world over the past
decade, largely due to the introduction of combination
antiretroviral therapy (ART) [1]. Widespread use of ART
has reduced nearly all of the complications of advanced
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HIV infection and immunosuppression in regions where
therapy is available, including CNS opportunistic infec-
tions and the AIDS dementia complex (ADC) [2].
Although effective in suppressing infection, current ART
regimens do not eradicate HIV, and prolonged treatment
may be complicated by development of drug resistance
and an array of side effects [3]. A number of therapeutic
strategies have been introduced to prolong the effective-
ness of antiretroviral treatment while reducing drug expo-
sure. Although structured (or strategic) treatment
interruption (STI) was initially studied as a means of
enhancing HIV-specific immunity via an autovaccination
phenomena or reducing the levels of drug resistant HIV,
its potential therapeutic utility is now being studied pri-
marily as a way to maintain the immunologic and clinical
benefit of therapy while reducing drug-toxicity and drug-
costs [4]. Despite continued concerns over the safety of
interrupting therapy, a large proportion of subjects in clin-
ical practice interrupt therapy for reasons related to drug
toxicity, treatment fatigue and/or drug costs.
We undertook the current study to determine whether
interrupting therapy can cause deleterious CNS effects
that are not appreciated by clinical history and examina-
tion. We used archived specimens from study subjects
who had interrupted therapy and been followed by
repeated lumbar puncture (LP) and CSF analysis before
and at various times after remaining off treatment. As a
measure of neurological injury, we used concentrations of
the light chain of neurofilament protein (NFL). NFL is a
major structural component of myelinated axons, and the
CSF level can serve as a sensitive marker of axonal damage
in a number of conditions [5,6]. Both focal and systemic
ischemia cause neuronal damage detectable as a leakage
of NFL into the CSF proportional to the severity of the
injury [5,7,8]. In chronic disorders the release of NFL is
less pronounced but still raised to several times normal in
active degeneration of white matter or myelinated spinal
tracts, for example in multiple sclerosis and in amyo-
trophic lateral sclerosis [5,9,10]. Dementia of vascular eti-
ology with subcortical white matter pathology causes
moderately increased CSF NFL levels [11,12]. CSF NFL
determination has thus been shown to be a versatile tool
to detect neuronal damage of any cause, prompting efforts
to develop alternate methods of analysis [6,13,14].
In a previous study, increased CSF NFL concentrations
were found in 12 of 18 AIDS patients without CNS oppor-
tunistic infections, but in only three out of 12 subjects
with less advanced, asymptomatic HIV-1 infection [15].
Materials and methods
Study subjects
We retrospectively identified subjects from two centers
who underwent serial lumbar punctures before and after
interruption of a combination antiretroviral regimen,
who had undetectable HIV RNA levels in CSF at the time
of the interruption and who had longitudinal samples
available for our studies. All subjects participated in sepa-
rate local protocols evaluating the CSF responses to
changes in antiretroviral treatment. Decisions to interrupt
treatment were made by the subjects and their primary
caregivers independent of the CSF studies. The protocols
were approved by University of California San Francisco
(UCSF) Committee on Human Research (CHR) and by
the Research Ethics Committee of Göteborg University.
All subjects provided informed consent.
CSF viral dynamics from some of these subjects have been
previously described [16,17].
Laboratory methods
CSF concentrations of NFL were analysed using a previ-
ously described ELISA [5]. In brief, capturing antibody
(hen anti-NFL IgG) was absorbed to microtest plates, and
CSF samples or reference NFL were then incubated. Rabbit
anti-NFL was used as secondary antibody. Bound second-
ary antibody was detected using peroxidase conjugated
donkey anti-rabbit IgG. The sensitivity of the assay is 125
ng/L, and the upper normal reference value at the labora-
tory is 250 ng/L below the age of 60 years.
Cell-free CSF and plasma HIV-1 RNA were quantified with
the Amplicor HIV-1 Monitor assay, version 1.5 (Roche
Diagnostic System, Hoffman-La Roche, Basel, Switzer-
land) with a dynamic range down to 50 copies/mL and a
detection limit of approximately 20 copies/mL.
Neopterin was measured by a commercially available
radio-immunoassay (Henningtest Neopterin, BRAHMS,
Berlin, Germany) with a normal reference value of ≤ 4.3
nmol/L in CSF [18].
Routine CSF assessments included CSF white blood cell
(WBC) count and peripheral blood CD4+ T-lymphocyte
(CD4) cell determination. Albumin was measured using
standard Clinical Laboratory methods in each center, and
the CSF:serum albumin ratios were calculated [CSF albu-
min (mg/L)/serum albumin (g/L)] and used as a measure
of blood-brain barrier integrity [19]. The five San Fran-
cisco patients also underwent standardized neurological
performance testing incorporating four tasks (timed gait,
grooved pegboard with the dominant hand, finger tap-
ping with the nondominant hand, and the Digit Symbol
test of the WAIS-R), yielding an aggregate scaled z-score
termed the QNPZ-4 score [20].AIDS Research and Therapy 2005, 2:6 http://www.aidsrestherapy.com/content/2/1/6
Page 3 of 7
(page number not for citation purposes)
Statistics
Unless otherwise indicated, descriptive group statistics in
this small study are presented as median values with the
range of values, and comparisons between subjects with
and without increases in CSF NFL used the Mann-Whitney
U test.
Results
Baseline characteristics
Eight subjects, five from San Francisco, California, USA
and three from Göteborg, Sweden were included in the
study. Demographic and baseline characteristics of the
subjects are listed in Table 1. All had CSF HIV RNA con-
centrations <50 copies/mL and were neurologically nor-
mal except for one identified as manifesting AIDS
dementia complex (ADC) Stage 0.5 (equivocal/subclini-
cal) disease on treatment. LPs were performed at various
intervals before treatment was stopped and one to six
(mean 2.9) times during the period off treatment. In two
subjects (207 and 223) CSF results were also available
from before the initiation of treatment.
Changes in CD4-cell count, HIV RNA levels and pleocytosis
The time course of changes in subjects' salient laboratory
findings are shown in Figure 1.
The peripheral blood CD4-cell count decreased from a
median of 446 cells/µL (range, 275–834) while on treat-
ment to 258 (208–738) cells/µL during the off-treatment
follow-up.
All 8 subjects developed an increase in CSF and plasma
HIV RNA concentrations. At baseline, the CSF HIV-1 RNA
was <50 (<1.70 log10) copies/mL in all subjects, and the
plasma HIV RNA levels was undetectable in six subjects.
The median viral load increased to a maximum of 4.36
(3.38–4.87) log10 RNA copies/mL in CSF and to 5.23
(4.78–6.35) log10 copies/mL in plasma during the inter-
ruption period. All but one of the subjects developed an
increase in CSF WBCs. CSF cell counts increased from a
median of 0.5 (range, 0–4) cells/µL on treatment to a
maximum of 14 (2–62) cells/µL after stopping therapy.
NFL
Three subjects developed elevations in NFL (panels A, B
and C), while the remaining five subjects did not (panels
D-H). As shown in the middle panels of each triplet set, all
eight subjects had normal CSF NFL concentrations (<250
ng/L) while on treatment, with six of these below the
detection limit (125 ng/L). For two subjects (223 and 207,
panel series C and G), CSF samples were also available
before initiation of antiretroviral treatment, 9–14 months
prior to baseline, and CSF NFL concentrations were found
to be <125 ng/L at these intervals as well. Treatment inter-
ruption resulted in CSF NFL increases in the three subjects
(6012, 6011 and 223, panels A-C), rising from baselines
at the detection limits to maximum values of 880 ng/L at
day 148 (6011), 10,930 ng/L at day 101 (6012) and 1,010
ng/L at day 58 (223). These increases were delayed in
relation to virological changes. In subject 223 the only
interval testing after treatment stopped was at day 58,
while in the two others who had more frequent measure-
ments the earliest documented increase in NFL for subject
6012 was at day 59 and for subject 6011 the inflection
point showing the initial increase was delayed to 86 and
99 days.
In the two subjects with increases in NFL and more fre-
quent measurements, the rise in plasma and CSF HIV RNA
preceded that of NFL, with the plasma HIV rising by the
first sampling at 17 and 15 days and the CSF by days 38
and 36. By contrast, the first change in NFL was delayed by
an additional three to seven weeks. The change from base-
line to maximum post-STI HIV RNA in blood and CSF was
Table 1: Baseline characteristics of patients.
Subject ID Age Sex Blood CD4+ CDC Stage ADC Stage HIV-1 RNA Antiretroviral therapies
baseline (nadir) CSF Plasma
(years) (cells/µL) (log10 copies/ml)
San Francisco
6004 56 M 275 (116) B3 0 <1.29 4,11 d4T,3TC,IDV
6008 39 M 834 (360) A2 0 1,61 <1.29 SQV, RTV
6011 47 M 375 (191) B3 0,5 <1.29 1,41 ZDV, 3TC, EFV
6012 54 M 464 (199) B3 0 <1.29 1,57 d4T, 3TC, EFV
6013 44 M 618 (275) C2 0 <1.29 3,69 d4T, 3TC, EFV
Göteborg
160 51 M 544 (195) C3 0 <1.29 <1.29 ZDV, 3TC, IDV
207 47 M 428 (210) A2 0 <1.29 <1.29 ZDV, 3TC, SQV, NFV
223 56 F 365 (110) B3 0 <1.29 <1.29 ZDV, 3TC, IDV/RTVAIDS Research and Therapy 2005, 2:6 http://www.aidsrestherapy.com/content/2/1/6
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not notably different in the three subjects with increases
in NFL compared to those without any change in this neu-
ral marker. There was no clear association of NFL eleva-
tion with that of CSF WBCs; indeed, the one subject
without CSF pleocytosis (6012, panel A) had the greatest
increase in CSF NFL.
Time course of changes in salient laboratory findings in the eight subjects (A-H) Figure 1
Time course of changes in salient laboratory findings in the eight subjects (A-H). Sets of three graphs for each subject arranged 
within eight panels (the top graph in each panel shows the changes in plasma and CSF HIV RNA and CSF WBCs, the center 
graph the NFL and QNPZ-4 for those with this assessment, and the bottom graph the blood and CSF neopterin and blood 
CD4+ T cell counts).
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The subjects were all clinically stable during the period of
observation (median 108, range 30–446 days, after
treatment interruption). None developed either AIDS-
related events or neurological symptoms during the off-
treatment follow-up. Likewise, their neurological exami-
nations were unchanged, and in the five tested for
quantitative neurological performance (including two
with NFL elevations – subjects 6012 and 6011), none
showed deterioration in their QNPZ-4 scores (shown in
middle graphs of subjects' triplet panels).
Changes in neopterin and its relationship to NFL
In keeping with the inflammatory response in CSF, all
subjects in which CSF and serum neopterin were meas-
ured exhibited an increase in this marker while off therapy
with the exception of subject 160 (panel H in the figure
1). CSF neopterin rose from a median of 6.65 (range,
1.80–16.4) to 23.0 (6.30–90.0) nmol/L in the six subjects
analysed. Where the timing could be evaluated, the peak
increase in CSF neopterin appeared to be delayed com-
pared to that of CSF HIV, and in subjects 6012 and 6011
occurred near the time of NFL rise. However, based on
these limited data, it was not clear that increases in CSF
neopterin correlated with increases in NFL. For example,
the increase in CSF neopterin in subject 207 (panel G)
exceeded that of subjects 6012 and 6011 despite contin-
ued undetectable CSF NFL.
The CD4-cell decreases began earlier than the increases in
NFL in subjects 6012 and 6011. Again, there was no clear
association of development of NFL increase with baseline
or nadir CD4 counts or the magnitude of their cell
decline. Also, only one subject (223) showed evidence of
blood-brain barrier disruption with an elevated
CSF:serum albumin ratio. In all others the albumin ratios
were stable or showed only minor change that did not
parallel changes in CSF NFL (data not shown). As
expected within this small dataset, no statistical signifi-
cant difference could be found between subjects with or
without CSF NFL increase, neither regarding the magni-
tude of increase in CSF neopterin, CSF WBC, CSF nor
plasma viral load (data not shown).
Discussion
While the use of STI to stimulate and boost the immune
system by re-exposure to viral antigens has not been
proved effective and may be complicated by enduring T
cell loss and enhanced resistance [4,21], there is still inter-
est in judicious suspension of therapy in order to reduce
cost and, more particularly, side effects of therapy. Addi-
tionally, patients may stop treatment for personal reasons
or because of toxicities. Our observation of increased CSF
NFL in three of eight subjects raises a previously unexam-
ined potential concern when interrupting antiretroviral
treatment – the possibility of nervous system injury –
although further studies are needed to confirm the fre-
quency of this finding and, more particularly, to under-
stand its pathobiological and clinical implications.
The neurofilament is a major structural element of neu-
rons, found most conspicuously in larger neurons and
their myelinated axons. It is composed of a triplet protein
of which the light subunit (NFL) is an essential compo-
nent of the neurofilament core. Its main function is to
maintain the axonal calibre and it thereby has a crucial
role in the structural and functional integrity of axons and
in their capacity to rapidly conduct nerve impulses [22].
Increased CSF NFL concentrations are thought to reflect
principally injury of myelinated axons, and a clear associ-
ation has been found between the presence of white mat-
ter changes and increased CSF NFL levels in patients with
Alzheimer's disease and subcortical vascular dementia
[12]. CSF NFL is also increased in several other neurode-
generative disorders linked to demyelination and/or
axonal degeneration, including active multiple sclerosis
and amyotrophic lateral sclerosis [5,10].
CSF NFL increased substantially in three of our eight sub-
jects studied after stopping antiretroviral therapy, thereby
indicating brain injury in this setting. The mechanisms
responsible for this rise in NFL remain to be determined.
Indeed, from a virological perspective, it is uncertain
whether the increase in NFL is simply a complication of
established viremia or is related more particularly to the
abrupt surge in viral replication that follows treatment
interruption. In other words, was this neurological dam-
age due simply to higher levels of HIV replication or due
to the "shock" associated with a rapid resurgence after
interruption? Perhaps favouring the latter is the finding of
elevations in NFL in these subjects without an AIDS diag-
nosis and CD4 counts above 200 cells/µL, contrasting
somewhat with our earlier study that showing CSF NFL
elevations chiefly in subjects with AIDS or with CNS
opportunistic infections [15]. Normal CSF NFL concentra-
tion in one patient measured before treatment initiation
gives further support to a rapid viral rebound as the trig-
gering event.
As seen by others [23], plasma viral load increased rapidly
and was already detected at the first follow-up (median 18
days) after treatment interruption. Subsequently, CSF
viral load increased after a short interval in the subjects
with sufficient observations to define these temporal rela-
tionships. In a larger experience, that included some of
these same subjects, we have noted this delay and also
found that an increase in CSF lymphocytosis developed in
more than half of subjects [16,17].
The current study also shows that STI leads to increases in
CSF and plasma neopterin levels and that these elevationsAIDS Research and Therapy 2005, 2:6 http://www.aidsrestherapy.com/content/2/1/6
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peak later than plasma and CSF HIV RNA levels.
Neopterin is an unspecific marker of immune activation
that is largely derived from activated macrophages and
microglia [24]. CSF neopterin is increased in patients with
ADC and has also been found to be a predictive marker of
ADC [25]. However, CSF neopterin is also frequently
increased in HIV-infected patients without neurological
complications, with higher levels found in severely immu-
nocompromised patients than in those with CD4-cell
counts above 200 cells/µL [26]. In a previous study, we
found an association between increased NFL and CSF
neopterin concentrations [15]. This led to our suggesting
that immune activation was important in the neuronal
injury and release of NFL in this setting. While elevations
in CSF neopterin were found in all the subjects with
increased NFL and there was the suggestion of temporal
association, we also observed subjects with elevated CSF
neopterin and normal, unchanging CSF NFL. Hence, fur-
ther studies are needed to examine this association.
Whatever the underlying mechanism, the presumed
axonal damage was subclinical, and no concomitant neu-
rological deterioration was detected during the follow-up
period either on the basis of symptoms or on clinical or
more formal, though brief, quantitative testing. Based on
this initial study, it remains unknown whether this axonal
injury has clinical importance. The subject number was
small and the follow-up period, for the most part, of lim-
ited duration. Hence, longer-term impact on neurological
function could not be discerned, though one subject was
followed for two years off treatment and did not exhibit
neurological change over that time. With one exception
(this same subject, 6011, with ADC 0.5 [27]), our subjects
were neurologically normal and without prior evidence of
ADC. Theoretically, for patients with ADC, resurgence of
viremia and CNS infection might be more hazardous, and
stopping treatment should be undertaken with particular
caution. Whether treatment approaches with repeated
cycles of treatment interruptions also can initiate repeated
damage to the brain is an open question.
The present study also does not establish whether axonal
injury is an acute short-term event after treatment inter-
ruption or if it is more chronic. In herpes simplex type 1
(HSV-1) encephalitis, CSF NFL levels increase to a maxi-
mum approximately 8–14 days after the onset of neuro-
logical symptoms, and only slowly decrease thereafter,
with abnormal levels still detected as long as 3–10
months later [28]. Similar observations, with slow nor-
malization of CSF NFL concentrations, have also been
made after focal brain ischemia and after acute relapses of
multiple sclerosis [10]. Wallerian degeneration, with an
anterograde degeneration of axons and disruption of the
axonal cytoskeleton, has been suggested as a principal
cause of this delayed and long-lasting CSF NFL increase in
these settings. The metabolic degradation and half-life of
NFL in CSF is also not established.
The temporal delay between viral replication (as evi-
denced by plasma and more particularly CSF HIV RNA
levels) and the onset of axonal disturbance (measured by
NFL) may also imply that Wallerian degeneration is
involved in STI. If the neuronal soma is the primary site of
action, the axonal changes should be a later event. A direct
effect on axons in myelinated tracts or spinal roots could
also be hypothesised. Alternatively, there may be a lag
between HIV replication and onset of neural injury, per-
haps involving immunopathological pathways that lag
behind the surge in viral replication. The magnitude of the
CSF viral load increase, however, did not directly predict
the development of elevated CSF NFL; as noted earlier,
there were subjects with high CSF viral load without
change in NFL levels.
Conclusion
In conclusion, our study raises the question of whether
treatment interruption enhances the risk of brain injury.
Conversely, it may also suggest that once started, contin-
ued treatment might prevent subclinical brain damage.
NFL is a sensitive marker of axonal injury which in the
present setting seems to disclose subclinical injury. Fur-
ther studies are needed to define the frequency, duration,
magnitude and pathobiological importance of this
increase in CSF NFL in HIV infection.
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